Mostrando 10 resultados de: 12
Filtros aplicados
Publisher
Cancer Biology and Therapy(3)
BMC Cancer(1)
BioPharm International(1)
Cancer Research(1)
European Journal of Pharmaceutical Sciences(1)
Área temáticas
Enfermedades(12)
Farmacología y terapéutica(6)
Fisiología humana(2)
Fisiología y materias afines(1)
Física aplicada(1)
Área de conocimiento
Cáncer(7)
Inmunología(4)
Medicina interna(3)
Biotecnología(1)
Descubrimiento de fármacos(1)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(12)
ODS 10: Reducción de las desigualdades(10)
ODS 17: Alianzas para lograr los objetivos(2)
Origen
scopus(12)
A view on EGFR-targeted therapies from the oncogene-addiction perspective
ArticleAbstract: Tumor cell growth and survival can often be impaired by inactivating a single oncogen - a phenomenonPalabras claves:CETUXIMAB, Combination therapy, eGFR, Erlotinib, nimotuzumab, Oncogene addiction, Targeted therapyAutores:de Leon J., Moreno E., Pérez R., Tania CrombetFuentes:scopusBivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile
ArticleAbstract: Nimotuzumab is an EGFR-targeting antibody that has demonstrated encouraging clinical results in thePalabras claves:Affinity, Avidity, Cancer immunotherapy, eGFR, monoclonal antibodies, nimotuzumab, Tumor targetingAutores:Fernandez L.E., Garrido G., Gracia E., Iznaga N., Kerbel R.S., Pérez R., Rabasa A., Tania Crombet, Tikhomirov I.A., Yang E.Fuentes:scopusAnti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule
ArticleAbstract: We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advancPalabras claves:antibodies affinity, cancer vaccine, EGF, NSCLC, surrogate biomarkerAutores:Alvarez K., Carmen Elena Viada, Fuentes K.P., García Verdecia B., González A., Gonzalez Z., Huerta V., Mazorra Z., Neninger Vinageras E., Popa X., Rodríguez P.C., Tania CrombetFuentes:scopusAntiproliferative, antiangiogenic and proapoptotic activity of H-R3: A humanized anti-EGFR antibody
ArticleAbstract: The epidermal growth factor receptor (EGFR) proto-oncogene is frequently overexpressed in tumors ofPalabras claves:Angiogenesis, Epidermal growth factor receptor (EGFR), H-R3, Monoclonal antibody, Signal inhibitorsAutores:Pérez R., Rak J., Tania Crombet, Viloria-Petit A.Fuentes:scopusAcquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis
ArticleAbstract: Inhibitors of epidermal growth factor receptor (EGFR) signaling are among the novel drugs showing grPalabras claves:Autores:Bohlen P., Hicklin D., Jothy S., Kerbel R.S., Rak J., Schlaeppi J.M., Tania Crombet, Viloria-Petit A.Fuentes:scopusIntegrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody
ArticleAbstract: The multiple-dose strategy with the monoclonal ior EGF/r3 antibody, in xenograft bearing nude mice,Palabras claves:Allometric scaling, Dosage regimen, Integrated pharmacokinetic-pharmacodynamic, Monoclonal antibody ior EGF/r3, Survival time, Tumor growth delayAutores:Alonso K., Alvarez D., Beausoleil I., Bécquer M.d.l.A., Castillo R., Duconge J., Fernández-Sánchez E.M., Matheu J., Tania Crombet, Valenzuela-Silva C.M., Vecino G.Fuentes:scopusIdentifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients
ArticleAbstract: Background: Immunosenescence biomarkers and peripheral blood parameters are evaluated separately asPalabras claves:Causal inference, CIMAvaxEGF, Non-small-cell lung cancer, Pbkp_redictive biomarkersAutores:Alonso A., Lage Davila A., Luaces P.L.o., Molenberghs G., Saavedra Hernández D., Sánchez L., Tania Crombet, Van der Elst W.Fuentes:scopusImmune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody
ArticleAbstract: SARS-CoV-2 infection causes a range of clinical presentations and induces changes in both innate andPalabras claves:covid-19, eGFR, inflammation, nimotuzumab, SARS-COV-2, T cellsAutores:Añe-Kouri A.L., Armada J.J., González Y.Z., Gregorich E.M.L., Londres H.D., Luaces P.L.o., Martínez A.H., Medel L., Mena J., Ramos M., Saavedra Hernández D., Sánchez Y.H., Tania Crombet, Troche M.Fuentes:scopusSystemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab
ArticleAbstract: Nimotuzumab (h-R3) is a humanized anti-epidermal growth factor receptor monoclonal antibody (mAb) rePalabras claves:animal model, CETUXIMAB, Epidermal growth factor receptor, General toxicity, H-R3, Monkeys, nimotuzumab, Skin toxicityAutores:Arteaga M.E., Ballester-Labrada A., Baro F., Boleda M., Casacó Parada A.R., Charro L., Fuentes D., García M., González B., González C., Hernández O., Ledón N., Macías A.E., Morales Y., Orphee R., Pardo B., Pérez A., Ramos M., Rodríguez V., Rodriquez L., Subirós N., Tania Crombet, Viña L.Fuentes:scopusTreatment of malignant, non-resectable, epithelial origin esophageal tumors with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy
ArticleAbstract: Overexpression of epidermal growth factor receptor in esophageal cancer is associated with poor progPalabras claves:Chemorariotherapy, Esophageal cancer, Humanized monoclonal, nimotuzumabAutores:Albuerne Y.A., Alert J., Alvarez E.S., Callejo I.P., De La Vega H.A., Gonzalez C.E.V., Gonzalez Y.S., Hernadez I.M., Lazo N.G., Luaces P.L.o., Martell J.A.n., Moreno B.P., Perez M.L., Ramos-Suzarte M., Ruiz-Garcia E.B., Soriano J.L., Tania CrombetFuentes:scopus